Capricor initiates dosing in Phase 2 COVID-19 trial

Capricor Therapeutics

Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19.

CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy designed to modulate COVID-19-associated cytokine storm.

The trial will enroll 60 patients who have been diagnosed with SARS-CoV-2 and require supplemental oxygen. The study’s primary objectives are to determine the safety and effectiveness of intravenously infused CAP-1002 for improving clinical outcomes in severe-to-critical COVID-19 patients. 

“As hospitalizations continue to increase, we have a therapeutic under investigation for patients at a high-risk for significant morbidity or even death,” Linda Marbán, Capricor’s CEO, said in a statement.

“It is important to remember that many patients are suffering from long term cardiac consequences from COVID-19. As CAP-1002 directly targets cardiac dysfunction, CAP-1002 potentially may also be an important tool in the treatment of the cardiac complications of COVID-19,” she added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.